CADL
VENTE TOTALE: 280 245 titres (~3 160 783,32 $ US)
- Insiders
- Tak Paul Peter
- Total bought
- —
- Total sold
- $3,160,783
- Last activity
- 2026-09-11
- Last synced
-
2026-09-13 10:23:38
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-12
CADL presents a deeply concerning profile combining severe financial distress (zero revenue, persistent operating losses, negative ROA/ROE) with a complete absence of meaningful catalysts.
The first sentence of the analysis written for CADL on 2026-09-12 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 100.0% | 100.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | -13668.8% | -28899.2% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | -13046.4% | -28899.2% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | -27739.2% | -20580.8% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | -15035.2% | -28899.2% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | -15035.2% | -28899.2% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | -15035.2% | -28899.2% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | -15035.2% | -28899.2% | |
| Current Ratio | 13.308 | 2.766 | 2.594 | 12.813 | 15.842 | |
| Quick Ratio | 13.308 | 2.766 | 2.594 | 12.813 | 15.842 | |
| Solvency Ratio | -0.510 | -1.337 | -1.300 | -0.585 | -1.441 | |
| Cash Ratio | 13.308 | 2.735 | 2.497 | 12.477 | 15.413 | |
| Price To Earnings Ratio | -7.847 | -4.989 | -1.122 | -18.008 | -4.094 | |
| Price To Earnings Growth Ratio | 0.134 | -0.152 | -0.001 | 0.190 | -0.066 | |
| Forward Price To Earnings Growth Ratio | 0.134 | -0.152 | -0.001 | 0.190 | -0.066 | |
| Price To Earnings Diluted Ratio | -7.847 | -4.989 | -1.122 | -18.008 | -4.094 | |
| Price To Earnings Diluted Growth Ratio | 0.134 | -0.152 | -0.001 | 0.190 | -0.066 | |
| Price To Book Ratio | 5.763 | 4.145 | 3.337 | 1.081 | 2.301 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 412.752 | 1,180.698 | |
| Price To Free Cash Flow Ratio | -7.692 | -10.168 | -1.226 | -1.577 | -6.136 | |
| Price To Operating Cash Flow Ratio | -7.810 | -10.174 | -1.242 | -1.642 | -6.643 | |
| Debt To Assets Ratio | 0.015 | 0.126 | 0.552 | 0.290 | 0.006 | |
| Debt To Equity Ratio | 0.037 | 0.203 | 1.786 | 0.478 | 0.009 | |
| Debt To Capital Ratio | 0.035 | 0.169 | 0.641 | 0.323 | 0.009 | |
| Long Term Debt To Capital Ratio | 0.027 | 0.038 | 0.493 | 0.304 | 0.009 | |
| Financial Leverage Ratio | 2.411 | 1.611 | 3.233 | 1.646 | 1.391 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.002 | 0.002 | |
| Operating Cash Flow Ratio | -4.258 | -0.720 | -2.414 | -5.596 | -4.144 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | -251.352 | -177.744 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.015 | 1.001 | 1.013 | 1.041 | 1.083 | |
| Debt Service Coverage Ratio | -13.736 | -4.347 | -2.993 | -7.508 | 0.000 | |
| Interest Coverage Ratio | -22.778 | -15.967 | -14.794 | -20.301 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | -86.092 | -2.731 | -3.851 | -67.713 | 0.000 | |
| Operating Cash Flow Coverage Ratio | -20.121 | -2.006 | -1.504 | -1.378 | -39.675 | |
| Capital Expenditure Coverage Ratio | -65.266 | -1,688.938 | -74.932 | -24.224 | -12.108 | |
| Dividend Paid And Capex Coverage Ratio | -65.266 | -1,688.938 | -74.932 | -24.224 | -12.108 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -5.150 | -3.566 | -0.869 | -0.266 | -1.813 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | ▼-40.0% |
| Ebit Margin | 0.0% | 0.0% | ▲8513.6% |
| Ebitda Margin | 0.0% | 0.0% | ▲8389.1% |
| Operating Profit Margin | 0.0% | 0.0% | ▲9664.0% |
| Pretax Profit Margin | 0.0% | 0.0% | ▲8786.9% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | ▲8786.9% |
| Net Profit Margin | 0.0% | 0.0% | ▲8786.9% |
| Bottom Line Profit Margin | 0.0% | 0.0% | ▲8786.9% |
| Current Ratio | 13.308 | ▲10.542 | ▲3.843 |
| Quick Ratio | 13.308 | ▲10.542 | ▲3.843 |
| Solvency Ratio | -0.510 | ▲0.827 | ▲0.525 |
| Cash Ratio | 13.308 | ▲10.573 | ▲4.022 |
| Price To Earnings Ratio | -7.847 | ▼-2.859 | ▼-0.635 |
| Price To Earnings Growth Ratio | 0.134 | ▲0.286 | ▲0.113 |
| Forward Price To Earnings Growth Ratio | 0.134 | ▲0.286 | ▲0.113 |
| Price To Earnings Diluted Ratio | -7.847 | ▼-2.859 | ▼-0.635 |
| Price To Earnings Diluted Growth Ratio | 0.134 | ▲0.286 | ▲0.113 |
| Price To Book Ratio | 5.763 | ▲1.618 | ▲2.437 |
| Price To Sales Ratio | 0.000 | 0.000 | ▼-318.690 |
| Price To Free Cash Flow Ratio | -7.692 | ▲2.476 | ▼-2.333 |
| Price To Operating Cash Flow Ratio | -7.810 | ▲2.364 | ▼-2.308 |
| Debt To Assets Ratio | 0.015 | ▼-0.111 | ▼-0.183 |
| Debt To Equity Ratio | 0.037 | ▼-0.166 | ▼-0.466 |
| Debt To Capital Ratio | 0.035 | ▼-0.133 | ▼-0.200 |
| Long Term Debt To Capital Ratio | 0.027 | ▼-0.010 | ▼-0.147 |
| Financial Leverage Ratio | 2.411 | ▲0.800 | ▲0.353 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | ▼-0.001 |
| Operating Cash Flow Ratio | -4.258 | ▼-3.538 | ▼-0.832 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | ▲85.819 |
| Free Cash Flow Operating Cash Flow Ratio | 1.015 | ▲0.015 | ▼-0.015 |
| Debt Service Coverage Ratio | -13.736 | ▼-9.389 | ▼-8.019 |
| Interest Coverage Ratio | -22.778 | ▼-6.811 | ▼-8.010 |
| Short Term Operating Cash Flow Coverage Ratio | -86.092 | ▼-83.361 | ▼-54.015 |
| Operating Cash Flow Coverage Ratio | -20.121 | ▼-18.115 | ▼-7.184 |
| Capital Expenditure Coverage Ratio | -65.266 | ▲1623.672 | ▲307.828 |
| Dividend Paid And Capex Coverage Ratio | -65.266 | ▲1623.672 | ▲307.828 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -5.151 | ▼-1.585 | ▼-2.818 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $299.2M | $274.9M | $42.5M | $51.6M | $147.6M | |
| Enterprise value | $181.4M | $185.8M | $29.9M | $4.3M | $65.5M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 34.69x | 524.04x | |
| EV / Op. cash flow | -4.74x | -6.87x | -0.87x | -0.14x | -2.95x | |
| EV / Free cash flow | -4.66x | -6.87x | -0.86x | -0.13x | -2.72x | |
| EV / EBITDA | -5.15x | -3.57x | -0.87x | -0.27x | -1.81x | |
| Net debt / EBITDA | 3.35x | 1.71x | 0.37x | 2.90x | 2.27x | |
| Current ratio | 13.31x | 2.77x | 2.59x | 12.81x | 15.84x | |
| Income quality | 1.00x | 0.49x | 0.90x | 1.67x | 0.61x | |
| Graham net-net | $1 | $2 | $0 | $1 | $3 | |
| Tax burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| Interest burden | 105.9% | 103.9% | 107.3% | 110.0% | 100.0% | |
| Working capital | $110.7M | $66.3M | $22.6M | $66.3M | $79.6M | |
| Invested capital | $110.7M | $69.0M | $26.6M | $71.8M | $83.4M | |
| Return on assets | -30.5% | -51.6% | -92.1% | -23.9% | -40.5% | |
| Operating ROA | -41.6% | -45.1% | -64.1% | -41.3% | -40.4% | |
| Return on tangible assets | -30.5% | -51.6% | -92.1% | -23.9% | -40.5% | |
| Return on equity | -73.5% | -83.2% | -297.7% | -39.4% | -56.3% | |
| Return on invested capital | -41.4% | -41.8% | -105.4% | -47.3% | -30.7% | |
| Return on capital employed | -41.5% | -48.1% | -142.1% | -47.6% | -30.7% | |
| Earnings yield | -12.8% | -20.1% | -89.2% | -36.4% | -24.5% | |
| Free cash flow yield | -13.0% | -9.8% | -81.6% | -63.4% | -16.3% | |
| Capex / Op. cash flow | -1.5% | -0.1% | -1.3% | -4.1% | -8.3% | |
| Capex / Depreciation | 69.5% | 1.6% | 47.6% | 166.7% | 790.9% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 1037.6% | 1468.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 11248.0% | 8538.4% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 16629.6% | 12142.4% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 1845.6% | 2370.4% | |
| Intangibles / Total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▲+8.8%EV / Sales n/aEV / EBITDA ▼-44.4%EV / Op. cash flow ▲+2.139Earnings yield ▲+0.073
Profitability
Return on equity ▲+0.097Return on assets ▲+0.211Return on invested capital ▲+0.004Return on capital employed ▲+0.066Operating ROA ▲+0.035Income quality ▲+0.514Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales n/aR&D / Sales n/a
Balance-sheet strength
Current ratio ▲+10.542Net debt / EBITDA ▲+1.634Working capital ▲+44459000.000Invested capital ▲+41726000.000Intangibles / Total assets n/a
Change over 5 years
Valuation
Market cap ▲+102.7%EV / Sales ▼-100.0%EV / EBITDA ▼-184.0%EV / Op. cash flow ▼-1.786Earnings yield ▲+0.117
Profitability
Return on equity ▼-0.172Return on assets ▲+0.100Return on invested capital ▼-0.107Return on capital employed ▼-0.109Operating ROA ▼-0.012Income quality ▲+0.388Tax burden 0.000
Efficiency
Days sales outstanding n/aDays payables outstanding n/aOperating cycle n/aCash conversion cycle n/aCapex / Sales ▼-14.680R&D / Sales ▼-121.424
Balance-sheet strength
Current ratio ▼-2.534Net debt / EBITDA ▲+1.073Working capital ▲+31151000.000Invested capital ▲+27315000.000Intangibles / Total assets n/a
Employee count
Peer market caps
Congressional trades
No congressional trade data synced.
Recent news
- 2026-09-10 Candel Therapeutics Appoints Martine Zimmermann, PharmD, to its Board of Directors NEEDHAM, Mass., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced the appointment of Martine Zimmermann, PharmD, to the Company''s Board of Directors (Board) effective September 8, 2026.
- 2026-09-01 Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEEDHAM, Mass., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on August 31, 2026, the Compensation Committee of Candel''s Board of Directors (the Board) granted to two new employees, stock options to purchase an aggregate of 31,400 shares of the Company''s common stock, with a per share exercise price of $13.07.
- 2026-08-26 Candel Therapeutics to Present at September Investor Conferences NEEDHAM, Mass., Aug. 26, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that Paul Peter Tak, M.D.
- 2026-08-16 Are Biotech Stocks The ''Comeback Kid'' Of 2026? I Say Yes Biotech, especially small-cap names, is experiencing renewed optimism as macro and policy headwinds subside, driving sector-wide rallies. Stabilization at the FDA and a resurgence in M&A and IPO activity are restoring capital flows and investor confidence in biotech equities.
- 2026-08-13 Candel Therapeutics Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights NEEDHAM, Mass., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve outcomes for patients with cancer, today announced financial results for the second quarter ended June 30, 2026, and provided a corporate update.
- 2026-08-12 Candel Therapeutics Eyes 2026 Prostate Cancer Filing as Lung Study Ramps Up Candel Therapeutics NASDAQ: CADL is advancing two off-the-shelf viral immunotherapy candidates designed for local administration intended to generate systemic immune responses against tumors, Chief Scientific Officer Francesca Barone said at the Canaccord Genuity Growth Conference in Boston.
- 2026-08-07 Candel Therapeutics: Getting Closer, And Building Out More Paths Candel Therapeutics, Inc. remains a Buy as its lead asset, CAN-2409, advances toward FDA submission in prostate cancer with strong phase 3 data. CADL is well-capitalized, holding $194.8M in cash, providing runway into Q1 2028 and supporting pivotal trials in prostate and lung cancer. CAN-2409''s phase 3 prostate cancer trial, conducted under Special Protocol Assessment, positions CADL for a potentially smoother regulatory review.
- 2026-08-03 Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that on July 31, 2026, the Compensation Committee of Candel''s Board of Directors (the Board) granted to three new employees, stock options to purchase an aggregate of 30,800 shares of the Company''s common stock, with a per share exercise price of $10.01.
- 2026-08-03 Candel Therapeutics to Present Extended Data from Phase 3 Results of Aglatimagene Besadenovec at ASTRO 2026 NEEDHAM, Mass., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that an abstract was accepted for poster presentation at the 2026 American Society for Radiation Oncology (ASTRO) Annual Meeting, taking place September 26-30, 2026, in Boston, MA.
- 2026-07-29 Candel Therapeutics to Present at Canaccord Genuity''s 46th Annual Growth Conference in Boston NEEDHAM, Mass., July 29, 2026 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal immunotherapies to improve disease outcomes for patients with cancer, today announced that the Company will present at Canaccord Genuity''s 46th Annual Growth Conference, taking place August 11-13, 2026, in Boston, MA.